KLOW Blend: GHK-Cu, BPC-157, TB-500 and KPV Explained
KLOW is an 80 mg four-peptide research blend combining GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg) and KPV (10 mg) in a single vial. It adds KPV, an alpha-MSH fragment researched in relation to inflammatory signalling in gut and skin models, to the three-peptide GLOW blend. Supplied for research use only, not for human consumption.
What is the KLOW blend?
KLOW is an 80 mg four-peptide research blend that combines GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg) and KPV (10 mg) in a single freeze-dried vial. It is built on the same composition logic as the GLOW blend, then extended with KPV, a tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that has been researched in relation to inflammatory signalling in gut and skin models. Where GLOW pairs a copper peptide with two additional peptides, KLOW adds a fourth peptide investigated for its anti-inflammatory activity in research settings. KLOW is supplied strictly for laboratory and educational research and is not for human consumption.
The name KLOW is simply GLOW with a K in front, signalling the single change: GLOW plus KPV. If you already understand GLOW, KLOW is that blend with a fourth peptide added to the inflammation-research side of the composition.
Each of the four peptides in KLOW has its own published research literature, and each has been studied in relation to a different biological pathway. GHK-Cu has been researched in relation to extracellular-matrix and collagen signalling, BPC-157 has been studied in gut and connective-tissue repair models, TB-500 has been studied in relation to cell migration and angiogenesis, and KPV has been studied in relation to inflammatory signalling. Blended together they are studied for complementary, non-overlapping mechanisms, which is the stated rationale for combining them rather than researching each in isolation.
The four peptides in KLOW, one at a time
KLOW is not a single molecule. It is a defined mixture of four peptides, each with a distinct structure, discovery history and research profile. Understanding what each one has been studied for is the fastest way to understand why the blend is put together the way it is.
- Structure: glycine-histidine-lysine bound to a copper ion (Gly-His-Lys-Cu), first identified in human plasma by Loren Pickart in 1973.
- Research angle: studied in relation to collagen and elastin synthesis, extracellular-matrix remodelling through regulation of matrix metalloproteinases, angiogenesis and antioxidant signalling.
- Role in KLOW: the structural, skin-and-collagen component of the blend, and the largest component by mass at 50 mg.
- Structure: a synthetic pentadecapeptide (15 amino acids) derived from a sequence in human gastric juice protein.
- Research angle: studied in preclinical models in relation to gut-lining protection, tendon and ligament repair, and VEGFR2 and angiogenic signalling; most available evidence is currently preclinical.
- Role in KLOW: the gut-and-connective-tissue research arm, overlapping with KPV in gut models and with TB-500 in soft-tissue models.
- Structure: a synthetic 43-amino-acid fragment of Thymosin Beta-4, a naturally occurring actin-sequestering protein.
- Research angle: studied in relation to cell migration via G-actin sequestration, angiogenesis through VEGF signalling, and macrophage polarisation in wound-healing models.
- Role in KLOW: the cell-migration and vascularisation research arm, complementing BPC-157 in soft-tissue repair research.
- Structure: the tripeptide lysine-proline-valine (Lys-Pro-Val), the C-terminal fragment of alpha-melanocyte-stimulating hormone.
- Research angle: studied in relation to anti-inflammatory activity through inhibition of NF-kB signalling, uptake into cells via the PepT1 transporter, and reported antimicrobial activity against organisms such as S. aureus and C. albicans in laboratory studies.
- Role in KLOW: the inflammation-research arm, and the peptide that distinguishes KLOW from GLOW.
Why these four peptides are blended together
The stated rationale for KLOW is mechanistic complementarity. Each peptide has been studied in relation to a different aspect of tissue-repair research, so combining them lets researchers study them together rather than one at a time. GHK-Cu contributes matrix-and-collagen research signalling, BPC-157 and TB-500 contribute overlapping but distinct tissue-repair and angiogenesis research pathways, and KPV contributes inflammation-related research. The result is a blend studied across the arc of a repair response as modelled in research: inflammatory signalling, cell migration and vascularisation, and matrix remodelling.
KLOW is GLOW plus a fourth, anti-inflammatory-researched peptide. GHK-Cu, BPC-157 and TB-500 cover matrix, repair and vascularisation research; KPV adds the inflammation-research arm that distinguishes the blend.
The gut is where the research overlap is most notable. BPC-157 has been studied in relation to protecting and regenerating the gastrointestinal lining, while KPV has been studied in relation to intestinal inflammatory signalling and is reported to be preferentially taken up by inflamed tissue via PepT1. On the skin side, GHK-Cu has been studied in relation to collagen and remodelling while KPV has been studied for its anti-inflammatory and antimicrobial activity in laboratory settings. This is why KLOW is framed around gut and skin research models specifically.
KLOW vs GLOW: what actually changes
The difference between KLOW and GLOW is one peptide and 10 mg of total content. GLOW is a 70 mg three-peptide blend (GHK-Cu 50, BPC-157 10, TB-500 10). KLOW keeps that exact trio and adds KPV 10 mg, taking the total to 80 mg. Everything in GLOW is retained in KLOW, with the KPV inflammation-research arm layered on top. Researchers comparing them are essentially deciding whether they want the additional anti-inflammatory and gut-and-skin research angle that KPV provides.
KLOW vs GLOW at a glance
| Attribute | GLOW | KLOW |
|---|---|---|
| Total content | 70 mg | 80 mg |
| GHK-Cu | 50 mg | 50 mg |
| BPC-157 | 10 mg | 10 mg |
| TB-500 | 10 mg | 10 mg |
| KPV | Not included | 10 mg |
| Peptide count | Three | Four |
| Primary research angle | Skin, hair and recovery models | Gut, skin and tissue-repair models |
| Distinguishing arm | Collagen and tissue-repair research | Adds inflammation research |
If you have read the NovaPeptides GHK-Cu and GLOW guides, KLOW is the logical next step: the same trio, plus KPV for the inflammation and gut-and-skin research angle.
KLOW blend composition table
The table below sets out the four KLOW components, their structural class and the research angle each contributes to the blend. Content figures are the labelled per-vial amounts that make up the 80 mg total.
KLOW four-component breakdown (80 mg total)
| Peptide | Content | Class | Researched in relation to |
|---|---|---|---|
| GHK-Cu | 50 mg | Copper tripeptide (Gly-His-Lys-Cu) | Collagen synthesis, matrix remodelling, skin and hair research |
| BPC-157 | 10 mg | Pentadecapeptide (15 amino acids) | Gut-lining and tendon or ligament repair models, angiogenesis |
| TB-500 | 10 mg | Thymosin Beta-4 fragment (43 amino acids) | Cell migration, angiogenesis, wound-healing signalling |
| KPV | 10 mg | Alpha-MSH C-terminal tripeptide (Lys-Pro-Val) | Anti-inflammatory NF-kB signalling, gut and skin models |
Note that the 80 mg figure describes the labelled content by mass. Because GHK-Cu is a larger, copper-complexed molecule and the other three are smaller peptides, mass proportion does not equal molar proportion. Researchers working with the blend should reason in terms of the amount of each named peptide rather than assuming an even split.
The research angle: gut, skin and tissue-repair models
KLOW is studied across three overlapping research areas. In gut models, BPC-157 and KPV are the primary interest: BPC-157 has been studied in relation to gastrointestinal-lining protection and repair, while KPV has been studied in published colitis models where it was reported to reduce inflammatory signalling, and is reported to be preferentially taken up by inflamed intestinal tissue through the PepT1 transporter. This pairing is the reason KLOW is framed as a gut-research blend as much as a skin one.
- Inflammation research: KPV has been studied in relation to inhibiting NF-kB and reducing pro-inflammatory cytokine signalling.
- Matrix and collagen: GHK-Cu has been studied in relation to collagen synthesis and extracellular-matrix remodelling.
- Cell migration and vascularisation: TB-500 has been studied in relation to G-actin sequestration and VEGF-driven angiogenesis.
- Barrier and connective-tissue repair: BPC-157 has been studied in relation to gut-lining and tendon or ligament repair in preclinical models.
- Skin surface: GHK-Cu and KPV together have been studied in relation to skin remodelling, anti-inflammatory and antimicrobial activity.
Most of the underlying evidence for BPC-157, TB-500 and KPV is preclinical (cell and animal models). No completed human trial has confirmed these outcomes in people. Efficacy remains under research, and KLOW is supplied for research use only, not for human consumption.
Supplied as a complete kit with a Novagen COA
KLOW is not sold as a loose vial. It ships as a complete research kit built around a reusable measuring pen, so a researcher receives everything needed to reconstitute and measure the blend in one box rather than sourcing parts separately. This is a deliberate difference from suppliers that ship a bare vial and a long syringe.
- One KLOW 80 mg freeze-dried peptide vial (GHK-Cu 50, BPC-157 10, TB-500 10, KPV 10).
- A reusable aluminium U-100 measuring pen for precise, click-based measurement.
- Bacteriostatic water for reconstitution.
- Multiple fine needle heads for the pen.
- A syringe and a thermal transit case.
- A full click and measurement reference for the pen, plus access to how-to videos and the interactive measurement tool.
Every KLOW batch is independently tested and ships with a Novagen Laboratories Certificate of Analysis (COA). Each COA carries a unique verification key that you enter at novagenlaboratories.com to confirm the report is genuine and matches your batch. Always verify the key on the certificate that arrives with your own kit rather than relying on any published figure.
COA verification is the single most important quality signal for a four-peptide blend, because a blend is only as trustworthy as the proof that all four components are actually present and correctly identified. Every NovaPeptides KLOW kit carries a verifiable Novagen COA with a unique key.
Research-use-only status and responsible framing
KLOW and every peptide it contains are supplied strictly for laboratory and educational research and are not for human consumption. Nothing on this page is medical advice, a dosing recommendation for people, or a claim that KLOW treats, cures, heals or is safe for any condition. The peptides are described only in terms of what published research has investigated them for, and much of that research is preclinical.
- KLOW is for research use only and is not for human consumption.
- Efficacy statements are hedged to what studies have investigated; no human outcomes are confirmed.
- No personal-use dosing protocol is provided; reconstitution and click references are for research measurement only.
- COA figures describe tested batch content and are not a safety or efficacy statement.
- For any enquiry, contact NovaPeptides via WhatsApp; the site is a catalogue and education resource with no cart or pricing.
Frequently asked questions
What is the KLOW blend?+
KLOW is an 80 mg four-peptide research blend containing GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg) and KPV (10 mg) in one freeze-dried vial. It is the three-peptide GLOW blend plus KPV, an alpha-MSH fragment researched in relation to inflammatory signalling in gut and skin models. KLOW is supplied for research use only, not for human consumption.
What is the difference between KLOW and GLOW?+
GLOW is a 70 mg three-peptide blend of GHK-Cu, BPC-157 and TB-500. KLOW keeps that identical trio and adds KPV 10 mg, bringing the total to 80 mg and the peptide count to four. The practical difference is the added KPV inflammation-research arm, which extends KLOW's research angle toward gut and skin inflammation models on top of GLOW's skin, hair and recovery research focus.
What does the K in KLOW stand for?+
The K signals KPV, the fourth peptide that separates KLOW from GLOW. KLOW is literally GLOW with a K added at the front, a shorthand for GLOW plus KPV. KPV is the lysine-proline-valine tripeptide, the C-terminal fragment of alpha-melanocyte-stimulating hormone, researched in relation to anti-inflammatory activity in gut and skin models.
What has each peptide in KLOW been researched for?+
GHK-Cu is a copper tripeptide studied in relation to collagen synthesis and matrix remodelling. BPC-157 is a pentadecapeptide studied in gut and tendon repair models. TB-500 is a Thymosin Beta-4 fragment studied in relation to cell migration and angiogenesis. KPV is an alpha-MSH tripeptide studied in relation to inflammatory NF-kB signalling. Together they have been studied across inflammation, vascularisation and matrix remodelling in research models.
Why are the four peptides blended together?+
They are blended for mechanistic complementarity. Each peptide has been researched in relation to a different aspect of the repair cascade, so combining them lets researchers study inflammation, cell migration, angiogenesis and matrix remodelling together rather than in isolation. KPV and BPC-157 overlap in gut models, while GHK-Cu, TB-500 and BPC-157 cover skin and soft-tissue research, which is why KLOW is described as a broad research blend.
What is KPV and why is it in KLOW?+
KPV is the tripeptide lysine-proline-valine, the C-terminal fragment of alpha-melanocyte-stimulating hormone. It has been researched in relation to anti-inflammatory activity through NF-kB inhibition, is reported to be taken into cells via the PepT1 transporter, and has shown antimicrobial activity in laboratory studies. In KLOW it provides the inflammation-research and gut-and-skin research arm that GLOW does not have.
Has KLOW been studied in relation to gut research?+
In research terms, yes. BPC-157 has been studied in relation to gastrointestinal-lining protection and repair, and KPV has been studied in colitis models where it was reported to reduce inflammatory signalling and was preferentially taken up by inflamed intestinal tissue via PepT1. This gut-focused pairing is a core part of KLOW's research profile, though the evidence is preclinical and unconfirmed in humans.
How much of each peptide is in KLOW?+
The labelled 80 mg total is GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. Because GHK-Cu is a larger copper-complexed molecule, mass proportion does not equal molar proportion, so researchers should reason in terms of each named peptide amount rather than assuming an even split. Every batch is independently tested and ships with a Novagen COA confirming the four components are present.
Is KLOW safe or approved for human use?+
No. KLOW and its four peptides are supplied strictly for laboratory and educational research and are not for human consumption. Much of the underlying evidence for BPC-157, TB-500 and KPV is preclinical, and no completed human trial has confirmed these outcomes in people. Nothing here is medical advice, a dosing recommendation, or a safety or efficacy claim.
How does KLOW relate to a Wolverine stack?+
The Wolverine stack is a well-known research pairing of BPC-157 and TB-500, studied for their complementary soft-tissue repair and angiogenesis research. KLOW contains that same BPC-157 and TB-500 pairing, then adds GHK-Cu for matrix and collagen research and KPV for inflammation research, making it a broader four-peptide research blend built around the Wolverine core.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp